Prati
Oleg Sofrygin
Oleg Sofrygin
Division of Research, Kaiser Permanente Northern California
Potvrđena adresa e-pošte na kp.org
Naslov
Citirano
Citirano
Godina
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review
TE Delea, J Edelsberg, O Sofrygin, SK Thomas, JF Baladi, PD Phatak, ...
Transfusion 47 (10), 1919-1929, 2007
2332007
Causal inference for social network data
EL Ogburn, O Sofrygin, I Diaz, MJ Van der Laan
Journal of the American Statistical Association 119 (545), 597-611, 2024
1422024
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system …
TE Delea, O Sofrygin, SK Thomas, JF Baladi, PD Phatak, TD Coates
Pharmacoeconomics 25, 329-342, 2007
1132007
Semi-parametric estimation and inference for the mean outcome of the single time-point intervention in a causally connected population
O Sofrygin, MJ van der Laan
Journal of causal inference 5 (1), 20160003, 2017
672017
Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists
M Vera-Llonch, E Massarotti, F Wolfe, N Shadick, R Westhovens, ...
The Journal of Rheumatology 35 (9), 1745-1753, 2008
562008
Child wasting and concurrent stunting in low-and middle-income countries
A Mertens, J Benjamin-Chung, JM Colford Jr, AE Hubbard, ...
Nature 621 (7979), 558-567, 2023
532023
Early-childhood linear growth faltering in low-and middle-income countries
J Benjamin-Chung, A Mertens, JM Colford Jr, AE Hubbard, ...
Nature 621 (7979), 550-557, 2023
49*2023
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
D Weycker, O Sofrygin, K Seefeld, RG Deeter, J Legg, J Edelsberg
BMC Health Services Research 13, 1-10, 2013
482013
Cost–effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate
M Vera-Llonch, E Massarotti, F Wolfe, N Shadick, R Westhovens, ...
Rheumatology 47 (4), 535-541, 2008
482008
Sequential double robustness in right-censored longitudinal models
AR Luedtke, O Sofrygin, MJ van der Laan, M Carone
arXiv preprint arXiv:1705.02459, 2017
472017
Robust and flexible estimation of stochastic mediation effects: a proposed method and example in a randomized trial setting
KE Rudolph, O Sofrygin, W Zheng, MJ Van Der Laan
Epidemiologic methods 7 (1), 20170007, 2018
432018
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
TE Delea, K El-Ouagari, J Karnon, O Sofrygin
Breast cancer research and treatment 108, 375-387, 2008
412008
sl3: Modern pipelines for machine learning and Super Learning
JR Coyle, NS Hejazi, I Malenica, RV Phillips, O Sofrygin
R package version 1 (2), 2021
402021
Mediation of neighborhood effects on adolescent substance use by the school and peer environments
KE Rudolph, O Sofrygin, NM Schmidt, R Crowder, MM Glymour, J Ahern, ...
Epidemiology 29 (4), 590-598, 2018
382018
Targeted learning with daily EHR data
O Sofrygin, Z Zhu, JA Schmittdiel, AS Adams, RW Grant, MJ van der Laan, ...
Statistics in medicine 38 (16), 3073-3090, 2019
372019
Use of machine learning to develop a risk-stratification tool for emergency department patients with acute heart failure
DR Sax, DG Mark, J Huang, O Sofrygin, JS Rana, SP Collins, AB Storrow, ...
Annals of Emergency Medicine 77 (2), 237-248, 2021
342021
Causes and consequences of child growth failure in low-and middle-income countries
A Mertens, J Benjamin-Chung, JM Colford Jr, J Coyle, MJ van der Laan, ...
MedRxiv, 2020.06. 09.20127100, 2020
342020
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria
TE Delea, O Sofrygin, JL Palmer, H Lau, VC Munk, J Sung, A Charney, ...
Journal of the American Society of Nephrology 20 (10), 2205-2213, 2009
342009
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
TE Delea, P Tappenden, O Sofrygin, D Browning, MM Amonkar, J Karnon, ...
The European Journal of Health Economics 13, 589-603, 2012
322012
Causes and consequences of child growth faltering in low-resource settings
A Mertens, J Benjamin-Chung, JM Colford Jr, J Coyle, MJ Van der Laan, ...
Nature 621 (7979), 568-576, 2023
302023
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20